Abstracts

Liver-Related Death in HIV/HCV Coinfected Individuals: Who Should Be Targeted for HCV Treatment?

Background: The arrival of potent and less toxic directly acting agents (DAA) for treatment of HCV infection may see improved outcomes and less toxicity among HIV coinfected patients. The costs of treatment may necessitate prioritisation of those at greatest risk of liver-related death (LRD) for therapy. Further understanding of LRD among HIV/HCV coinfected individuals is…

Short-term Risk of Decompensation Among HIV/HCV-Coinfected Patients With Significant Fibrosis

Background: Newer directly acting antivirals against (DAA) HCV are becoming available. Their efficacy and safety profile is better than that of telaprevir or boceprevir. Therefore,clinicians tend to defer therapy for patients at a seemingly low risk of liver decompensation (DC)in the short-term. Thus, individuals with F3-F4 by liver biopsy (LB) are given maximum treatment priority…

The Treatment Cascade for People With Chronic Hepatitis C Virus Infection in the United States

Background: As antiviral therapy for chronic hepatitis C virus (HCV) advances to become more convenient, effective, and better-tolerated, identifying gaps in HCV care will become increasingly important to clinicians, public health officials, and federal agencies. The objective of this study was to review the literature to estimate the number of chronic HCV-infected persons living in…

The Hepatitis C Cascade of Care Among HIV-Infected Patients Following Diagnosis of HCV Infection

Background: Guidelines recommend screening for hepatitis (HCV) in all HIV-infected individuals, but little is known about factors influencing HCV treatment referral and disposition following HCV diagnosis. We therefore conducted this study to investigate the HCV cascade of care for HIV patients with known HCV diagnosis and to identify reasons for not starting HCV therapy after…

Liver Fibrosis Is Not Uncommon in HIV-Infected Patients Without Viral or Alcoholic Hepatitis

Background: Liver fibrosis in HIV-infected individuals is mostly attributable to hepatitis B (HBV) or C (HCV) co-infection. An association between significant liver fibrosis and diabetes mellitus in an HIV-uninfected population has been reported, but this phenomenon in HIV mono-infected patients has not been well described, and few studies of liver fibrosis in HIV mono-infection have…

Prevalence of Liver Fibrosis Based on Non-invasive Markers Among HIV-Infected Patients in Zambia

Background: Liver-related mortality is anticipated to increase as HIV-infected individuals live longer in sub-Saharan Africa (SSA). Data on the epidemiology of liver fibrosis, an early form of chronic liver disease, from these populations are scarce. Using FIB-4 index and AST-to-platelet ratio index (APRI), we estimated the prevalence and factors associated with having significant fibrosis among…

Significance of Alcohol Abuse Diagnosis vs Other Risk Factors for Advanced Liver Fibrosis by FIB-4

Background: Liver disease has emerged as a major cause of non-AIDS-related death among patients with HIV. Given the limitations of liver biopsy, noninvasive markers of hepatic fibrosis such as FIB-4, an index derived from age, platelet count and aminotransferase levels (ALT, AST), have been validated and shown to predict both severity of fibrosis and clinical…

Microbial Translocation Immune Activation Apoptosis and Liver Fibrosis in the MASH Cohort

Background: Microbial translocation and immune activation occurs as HIV disease progresses and has been linked with the development of liver disease. Most of these studies however, have been done in vitro and in animal models. Our objective was to investigate the pathways of liver fibrogenesis, including microbial translocation, apoptosis, and cytokine activation in HIV mono-infected…